Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.

Dhodapkar MV, Richter J.

Clin Immunol. 2011 Aug;140(2):160-6. doi: 10.1016/j.clim.2010.12.010. Epub 2011 Jan 12. Review.

2.

Harnessing CD1d-restricted T cells toward antitumor immunity in humans.

Neparidze N, Dhodapkar MV.

Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.

3.

Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.

Rzemieniak SE, Hirschfeld AF, Victor RE, Chilvers MA, Zheng D, van den Elzen P, Turvey SE.

Immunology. 2010 Jun;130(2):288-95. doi: 10.1111/j.1365-2567.2009.03234.x. Epub 2010 Jan 19.

4.

Application of natural killer T cells in antitumor immunotherapy.

Hong C, Park SH.

Crit Rev Immunol. 2007;27(6):511-25. Review.

PMID:
18197797
5.

Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.

Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, Kim Y, Song H, Bogen B, Choi I.

Immunol Lett. 2013 Nov-Dec;156(1-2):132-9. doi: 10.1016/j.imlet.2013.10.002. Epub 2013 Oct 19.

PMID:
24148970
6.

NKT and tolerance.

Diana J, Beaudoin L, Gautron AS, Lehuen A.

Methods Mol Biol. 2011;677:193-206. doi: 10.1007/978-1-60761-869-0_14.

PMID:
20941612
7.

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Wu L, Gabriel CL, Parekh VV, Van Kaer L.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8. Review.

PMID:
19392798
8.

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.

Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, Krasovsky J.

J Exp Med. 2003 Jun 16;197(12):1667-76. Epub 2003 Jun 9.

9.

Human NKT cells express granulysin and exhibit antimycobacterial activity.

Gansert JL, Kiessler V, Engele M, Wittke F, Röllinghoff M, Krensky AM, Porcelli SA, Modlin RL, Stenger S.

J Immunol. 2003 Mar 15;170(6):3154-61.

10.

Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.

Fujii S, Shimizu K, Steinman RM, Dhodapkar MV.

J Immunol Methods. 2003 Jan 15;272(1-2):147-59.

PMID:
12505720
11.

Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.

Parekh VV, Singh AK, Wilson MT, Olivares-Villagómez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L, Wang CR, Joyce S, Van Kaer L.

J Immunol. 2004 Sep 15;173(6):3693-706.

12.

Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

Webb TJ, Bieler JG, Schneck JP, Oelke M.

J Immunol Methods. 2009 Jul 31;346(1-2):38-44. doi: 10.1016/j.jim.2009.05.003. Epub 2009 May 14.

13.

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E.

PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013.

14.

Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Padte NN, Li X, Tsuji M, Vasan S.

Clin Immunol. 2011 Aug;140(2):142-51. doi: 10.1016/j.clim.2010.11.009. Epub 2010 Dec 24. Review.

15.

Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Van Kaer L, Wu L, Parekh VV.

Immunology. 2015 Sep;146(1):1-10. doi: 10.1111/imm.12485. Epub 2015 Jun 22. Review.

PMID:
26032048
16.

Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.

Hogan AE, O'Reilly V, Dunne MR, Dere RT, Zeng SG, O'Brien C, Amu S, Fallon PG, Exley MA, O'Farrelly C, Zhu X, Doherty DG.

Clin Immunol. 2011 Aug;140(2):196-207. doi: 10.1016/j.clim.2011.03.016. Epub 2011 Apr 13.

PMID:
21493160
17.

B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.

Brandl C, Ortler S, Herrmann T, Cardell S, Lutz MB, Wiendl H.

PLoS One. 2010 May 24;5(5):e10800. doi: 10.1371/journal.pone.0010800.

18.

Natural killer T cell-mediated antitumor immune responses and their clinical applications.

Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M.

Cancer Sci. 2006 Sep;97(9):807-12. Epub 2006 Jun 29. Review.

19.

Harnessing invariant NKT cells in vaccination strategies.

Cerundolo V, Silk JD, Masri SH, Salio M.

Nat Rev Immunol. 2009 Jan;9(1):28-38. doi: 10.1038/nri2451. Review.

PMID:
19079136
20.

Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.

Choi DH, Kim KS, Yang SH, Chung DH, Song B, Sprent J, Cho JH, Sung YC.

Cancer Res. 2011 Dec 15;71(24):7442-51. doi: 10.1158/0008-5472.CAN-11-1459. Epub 2011 Oct 25.

Items per page

Supplemental Content

Write to the Help Desk